



PATIENT NAME GNMY9, ABNORMAL				ORDER NUMBER M724000360
PATIENT ID SA00158414	DATE OF BIRTH 12/14/1956	AGE 66 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/23/2023, 12:00 AM	RECEIVED 2/24/2023, 2:37 PM	REPORTED 3/1/2023, 3:06 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00158414 CLIENT MRN SA00158414

TEST DESCRIPTION

Evaluation of the MYH9 gene associated with MYH9-related disorders.

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
MYH9 NM_002473.5	c.2114G>A p.Arg705His Chr22:g.36702021C>T	heterozygous	PATHOGENIC

The following heterozygous PATHOGENIC variant was detected:

MYH9 (NM_002473.5), chr22(GRCh37):g.36702021C>T, c.2114G>A, p.Arg705His (p.R705H)

INTERPRETATION

MYH9 c.2114G>A (p.Arg705His), PATHOGENIC

The heterozygous c.2114G>A (p.Arg705His) missense variant in the MYH9 gene (MIM:160775) is classified as pathogenic. Pathogenic variants in the MYH9 gene have been associated with autosomal dominant MYH9-related disorders. This variant has been reported in many unrelated individuals with a MYH9-related disorder, both with and without hematological involvement (1-5). Furthermore, functional studies have been performed to support the pathogenicity of this variant. Functional studies demonstrate this alteration results in impaired motile activities and reduced thermal stability in an in vitro motility assay, as well as an altered phenotype in one cell line (6,7). This variant occurs in an established functional domain and an in silico meta-predictor suggests that this amino acid change may impact protein function. This variant is absent from large control databases (8,9). This result is supportive of a diagnosis of an MYH9-related disorder for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.



PATIENT NAME GNMY9, ABNORMAL				ORDER NUMBER M724000360
PATIENT ID SA00158414	DATE OF BIRTH 12/14/1956	AGE 66 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/23/2023, 12:00 AM	RECEIVED 2/24/2023, 2:37 PM	REPORTED 3/1/2023, 3:06 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER
7028846				SA00158414
MCL RochesterCampus				CLIENT MRN
Rochester MN 55901				SA00158414

REFERENCES:

- 1) Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet. 2000;67(5):1121-1128. doi:10.1016/S0002-9297(07)62942-5 (PMID 11023810)
- 2) Dantas VG, Lezirovitz K, Yamamoto GL, Moura de Souza CF, Ferreira SG, Mingroni-Netto RC. c.G2114A MYH9 mutation (DFNA17) causes non-syndromic autosomal dominant hearing loss in a Brazilian family. Genet Mol Biol. 2014;37(4):616-621. doi:10.1590/S1415-47572014005000025 (PMID 25505834)
- 3) Saposnik B, Binard S, Fenneteau O, et al. Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders. Mol Genet Genomic Med. 2014;2(4):297-312. doi:10.1002/mgg3.68 (PMID 25077172)
- 4) Verver E, Pecci A, De Rocco D, et al. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17. Clin Genet. 2015;88(1):85-89. doi:10.1111/cge.12438 (PMID 24890873)
- 5) Hildebrand MS, de Silva MG, Gardner RJ, et al. Cochlear implants for DFNA17 deafness. Laryngoscope. 2006;116(12):2211-2215. doi:10.1097/01.mlg.0000242089.72880.f8 (PMID 17146397)
- 6) Iwai S, Hanamoto D, Chaen S. A point mutation in the SH1 helix alters elasticity and thermal stability of myosin II. J Biol Chem. 2006;281(41):30736-30744. doi:10.1074/jbc.M605365200 (PMID 16901894)
- 7) Wei CC, Lalwani AK, Mhatre AN. In vitro expression and characterization of MYH9 mutant alleles linked to hereditary hearing loss. Otolaryngol Head Neck Surg. 2010;142(5):699-703. doi:10.1016/j.otohns.2009.12.030 (PMID 20416459)
- 8) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 1999;9:677-679 (PMID 10447503)
- 9) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the gene analyzed. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth >30X. Sensitivity is estimated at >99% for single nucleotide variants, >94% for indels up to 39 base pairs, >95% for deletions up to 75 base pairs and insertions up to 47 base pairs. NGS and/or a PCR-based quantitative method was performed to test for the presence of deletions and duplications in the gene analyzed. See the Genes Analyzed field for a list of gene(s) tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID GNMY9) for details regarding genes with regions not routinely covered.



PATIENT NAME GNMY9, ABNORMAL				ORDER NUMBER M724000360
PATIENT ID SA00158414	DATE OF BIRTH 12/14/1956	AGE 66 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/23/2023, 12:00 AM	RECEIVED 2/24/2023, 2:37 PM	REPORTED 3/1/2023, 3:06 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00158414
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00158414

GENES ANALYZED

MYH9

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID GNMY9) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.



1-800-533-1710
MYH9 Gene, Full Gene NGS

GNMY9

PATIENT NAME GNMY9, ABNORMAL				ORDER NUMBER M724000360
PATIENT ID SA00158414	DATE OF BIRTH 12/14/1956	AGE 66 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 2/23/2023, 12:00 AM	RECEIVED 2/24/2023, 2:37 PM	REPORTED 3/1/2023, 3:06 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00158414 CLIENT MRN SA00158414

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

SHANDA VOELTZ

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM MORICE MD, PHD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905